MedPath

Caffeine

Generic Name
Caffeine
Brand Names
Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
Drug Type
Small Molecule
Chemical Formula
C8H10N4O2
CAS Number
58-08-2
Unique Ingredient Identifier
3G6A5W338E
Background

Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.

Indication

Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.

Associated Conditions
Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
Associated Therapies
Analgesia, Antacid therapy, Athletic Performance

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

First Posted Date
2024-01-22
Last Posted Date
2025-03-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
16
Registration Number
NCT06215430
Locations
🇺🇸

Covance Clinical Research Unit, Dallas, Texas, United States

Caffeine and Training Intensity Quantification

Not Applicable
Not yet recruiting
Conditions
Caffeine
Interventions
First Posted Date
2024-01-18
Last Posted Date
2024-01-18
Lead Sponsor
St. Mary's University, Twickenham
Target Recruit Count
36
Registration Number
NCT06210984

the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy

Early Phase 1
Active, not recruiting
Conditions
Pharmacological Action of Drug
Interventions
First Posted Date
2023-10-24
Last Posted Date
2023-10-24
Lead Sponsor
Al-Azhar University
Target Recruit Count
50
Registration Number
NCT06097767
Locations
🇪🇬

NICU at Alzahraa University Hospital, Cairo, Egypt

Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress

Phase 2
Recruiting
Conditions
Prematurity
Respiratory Disease
Ventilator Lung; Newborn
Interventions
First Posted Date
2023-09-06
Last Posted Date
2025-01-03
Lead Sponsor
Ministry of Health, Saudi Arabia
Target Recruit Count
134
Registration Number
NCT06026163
Locations
🇸🇦

King Salman Bin Abdulaziz Medical City, Medina, Saudi Arabia

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

First Posted Date
2023-07-06
Last Posted Date
2023-10-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
22
Registration Number
NCT05932277
Locations
🇺🇸

ICON Lenexa, Lenexa, Kansas, United States

Caffeine in the Second Stage of Labor in Low-risk Nulliparous Mothers at Term

Phase 1
Not yet recruiting
Conditions
Second Stage of Labor
Interventions
First Posted Date
2023-06-15
Last Posted Date
2023-09-14
Lead Sponsor
The Reading Hospital and Medical Center
Target Recruit Count
80
Registration Number
NCT05906303
Locations
🇺🇸

Reading Hospital Labor & Delivery, West Reading, Pennsylvania, United States

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

First Posted Date
2023-05-10
Last Posted Date
2023-09-26
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
18
Registration Number
NCT05852769
Locations
🇺🇸

ICON plc, Millcreek, Utah, United States

Consequences of Caffeine Intake in Sleep Restricted Teenagers

Not Applicable
Recruiting
Conditions
Caffeine
Insufficient Sleep
Interventions
First Posted Date
2023-03-30
Last Posted Date
2023-05-25
Lead Sponsor
Psychiatric Hospital of the University of Basel
Target Recruit Count
54
Registration Number
NCT05790161
Locations
🇨🇭

Centre for Chronobiology, Basel, Switzerland

Oxygen Toxicity: Mechanisms in Humans

Not Applicable
Recruiting
Conditions
Seizures
Oxygen Toxicity
Hypercapnia
Interventions
First Posted Date
2023-03-09
Last Posted Date
2025-03-17
Lead Sponsor
Duke University
Target Recruit Count
62
Registration Number
NCT05761756
Locations
🇺🇸

Duke University Health Sustem, Durham, North Carolina, United States

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable
Completed
Conditions
Liver Cirrhosis
Interventions
First Posted Date
2023-02-23
Last Posted Date
2025-01-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4
Registration Number
NCT05741385
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath